Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

Intravesical gentamicin instillation cuts number of UTI episodes

09 Nov 2018

Intravesical instillation of gentamicin appears to result in reduced number of urinary tract infection (UTI) episodes and degree of antimicrobial resistance, a study has shown.

The study included 63 adults with recurrent UTI caused by multidrug-resistant (MDR) pathogens. All of them received overnight intravesical gentamicin instillations for 6 months.

Recurrence rate of UTIs, the primary study outcome, dropped from 4.8 at baseline to 1.0 during intravesical treatment. The secondary outcome of resistance to uropathogens also improved, with the rate falling from 78 percent to 23 percent.

In terms of safety, there were no reports of systemic absorption or clinically relevant side effects.

Intravesical instillations have long been used in urology, mostly for treating nonmuscle invasive bladder cancer. Gentamicin is believed to be an ideal antibiotic for intravesical instillation, having been shown to be bactericidal against most gram-negative genitourinary pathogens including some multiresistant organisms. Intravenous use of this drug is limited by potential nephrotoxic and ototoxic effects, although the bladder provides an impermeable surface and allows the drug to be concentrated at high levels in the target area. Another advantage of not administering it systemically is the avoidance of side effects such as nausea, diarrhoea and colonic superinfection. [Int J Antimicrob Agents 2010;36:485-490]

Recurrent UTIs are a common problem, negatively affecting quality of life and possibly requiring hospital admission. About one-third of females will have a UTI in their lifetime, with evidence showing that 24–50 percent of them will have a recurrence within 6 months of the index infection. [Neurourol Urodyn 2017;36:2109-2116]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.